Diagnostic
Help identify or classify a cancer.
UNDERSTAND MORE. FEAR LESS.
Cancer treatment increasingly depends not only on where a cancer started, but also on what makes that cancer biologically different.
Two cancers arising in the same organ may have different proteins, genes or molecular alterations. These biological features are often called biomarkers.
Some biomarkers can help doctors:
A biomarker is useful only when interpreted in the context of the cancer type, stage and treatment setting.
Explore the Cancer Tests & Investigations — A Complete Patient Guide for biopsy, scans, blood tests, preparation, report interpretation and questions to ask your team.
A cancer biomarker is a measurable biological feature of a tumour or cancer cell. It may be a protein, a gene mutation, extra copies of a gene (amplification), a gene rearrangement or fusion, a pattern of DNA-repair deficiency, a marker of immune activity or another molecular characteristic.
Biomarkers may be measured in tumour tissue, blood or occasionally other biological samples.
Not every biomarker is useful in every cancer.
The meaning of the same biomarker may differ with cancer type, stage, treatment history, available therapies and clinical guidelines.
Help identify or classify a cancer.
May provide information about how a cancer is likely to behave.
May help estimate whether a cancer is more or less likely to respond to a particular treatment.
Predictive and prognostic do not mean the same thing.
A biomarker that tells us something about prognosis does not necessarily identify a treatment.
No. Broad molecular testing is very useful in some cancers and treatment settings, but it is not automatically necessary for every patient.
Whether NGS is useful depends on:
The best test is not always the biggest test.
Sometimes one IHC, FISH or PCR test answers the clinical question more directly than a broad NGS panel. In other situations, broad NGS may be extremely valuable.
Immunohistochemistry, usually called IHC, uses antibodies to look for particular proteins in tumour tissue. It can help identify tumour type and likely origin, classify subtypes, assess selected predictive biomarkers and evaluate some DNA-repair proteins.
Examples include:
IHC usually answers a focused biological question.
One IHC result does not determine treatment in every situation. It is interpreted alongside the rest of the pathology report and diagnosis.
In-situ hybridisation (ISH) uses probes to examine selected genes or chromosomes within tumour cells. FISH is a form of ISH that uses fluorescent signals.
These tests may detect gene amplification, rearrangements or fusions, and selected chromosomal abnormalities. Examples include HER2 gene amplification or selected gene rearrangements, depending on the cancer.
FISH is a targeted test. It does not examine every gene in the tumour.
Not every patient requires FISH.
Polymerase chain reaction (PCR)-based testing can look for specific known genetic alterations. It may be useful when doctors are searching for a particular mutation, a limited group of mutations or another well-defined molecular alteration.
PCR can be very sensitive and efficient when the clinical question is already clearly defined.
Next-generation sequencing, or NGS, can examine many genes or genetic regions at the same time. Depending on the panel, it may identify mutations, insertions or deletions, gene amplifications, rearrangements or fusions, and other molecular alterations.
NGS may help identify approved targeted treatment options, resistance mechanisms, potential clinical-trial options or additional biological information.
Different NGS panels test different genes. A negative NGS test does not exclude every possible genetic alteration.
Interpretation depends on the genes and regions tested, the technology used, specimen quality, tumour content and reporting thresholds. DNA and RNA panels can have different strengths, particularly for detecting fusions.
Usually looks for: proteins.
Often useful when: a specific biological question is already known.
Examples: HER2 protein expression, hormone receptors, mismatch-repair proteins and PD-L1.
Usually looks for: multiple genetic alterations.
Often useful when: several potentially relevant genes need to be examined together.
Examples: selected mutations, amplifications and fusions, depending on the panel.
IHC and NGS are complementary tools. One does not automatically replace the other.
HER2 is a protein involved in cell growth. Some cancers have increased HER2 protein, increased copies of the HER2 gene, or other HER2-related alterations such as a gene mutation. These are different findings.
HER2 testing is particularly established in breast, gastric and gastro-esophageal cancers, and is relevant in selected other cancers. Testing may involve IHC, ISH/FISH or molecular testing, depending on the tumour and clinical situation.
HER2-positive does not mean the same thing in every cancer type.
Definitions, scoring and treatment implications depend on the specific tumour. In some settings, lower levels of HER2 expression may also matter; they are not interchangeable with HER2 gene amplification or mutation.
Read more about breast cancer subtypes in our Breast Cancer guide.
PD-L1 is a protein involved in regulating immune responses. Some cancer cells use the PD-1/PD-L1 pathway to reduce immune attack. PD-L1 testing is usually performed using IHC.
Reports may use different scoring systems, including tumour proportion score (TPS) or combined positive score (CPS). These scores are not interchangeable; the appropriate assay and threshold depend on the cancer and treatment.
PD-L1 is not a universal yes-or-no test for immunotherapy.
Its role depends on cancer type, stage, treatment setting, other biomarkers and the specific immunotherapy being considered. Some patients may benefit despite low PD-L1, while in other cancers PD-L1 is important for selecting treatment. A high score does not guarantee benefit.
Cells have systems that repair mistakes occurring during DNA replication. One is called mismatch repair. The main mismatch-repair proteins are MLH1, PMS2, MSH2 and MSH6.
When this system is not functioning properly, the tumour may be described as dMMR — deficient mismatch repair. A related test looks for MSI — microsatellite instability, changes in short repeated stretches of DNA. High microsatellite instability is called MSI-H.
dMMR and MSI-H are related but are tested differently. IHC examines mismatch-repair proteins; PCR or validated NGS methods can examine MSI. Occasionally results disagree and require specialist review.
MSI/MMR testing can affect treatment and may sometimes suggest an inherited cancer syndrome. Not every dMMR or MSI-H tumour is hereditary.
If an inherited syndrome is suspected, separate germline evaluation may be needed.
BRCA1 and BRCA2 are genes involved in repairing damaged DNA. Pathogenic alterations may be relevant in breast, ovarian, prostate, pancreatic and selected other cancers.
Present in the body’s normal cells from birth and potentially inherited or passed to biological children.
Acquired in tumour cells rather than inherited throughout the body.
A BRCA alteration found in a tumour does not automatically prove that it was inherited.
Separate germline testing may be required. The exact variant and whether it is known to be harmful matter.
HRD means Homologous Recombination Deficiency. It describes impairment in an important pathway used to repair DNA damage.
Some cancers with pathogenic BRCA alterations have HRD, but HRD can also arise through other mechanisms. Testing is particularly relevant in selected ovarian cancer settings; its use in other cancers depends on validated evidence and clinical context.
HRD is not a single gene test.
Different assays may measure HRD differently, for example by looking for patterns of genomic damage. The clinical meaning depends on the cancer, assay and treatment setting. An HRD-positive result does not mean that every cancer should receive the same therapy.
Certain alterations in the EGFR gene can act as drivers of cancer growth. EGFR testing is particularly important in selected patients with non-small-cell lung cancer.
Different EGFR alterations may have different treatment implications.
The exact alteration matters, together with the stage, previous treatment and other clinical findings.
Sometimes parts of two genes become abnormally joined. This may create a gene fusion that drives cancer growth. Examples include selected alterations involving ALK, ROS1, RET and NTRK.
These alterations are uncommon overall but can be very important when present. Depending on the gene and tumour, testing may use IHC, FISH, RNA-based testing or DNA-based NGS. IHC may be a screening step, with additional confirmation needed in some situations.
Rare biomarkers can still be clinically important.
BRAF is part of a cellular signalling pathway involved in cell growth. Certain BRAF alterations occur in several cancer types.
Not all BRAF alterations are biologically identical. Treatment implications depend on the exact alteration, cancer type and clinical context. A report saying “BRAF mutation” needs more detail before it can guide care.
KRAS is another important gene involved in cancer growth. Different KRAS alterations may have different clinical implications. G12C is one example of a specific variant; it does not have the same meaning as every other KRAS mutation.
The exact variant matters.
Depending on the cancer, doctors may also test genes such as MET, FGFR, PIK3CA, IDH, KIT, PDGFRA and ESR1, or other clinically relevant genes. This is not an exhaustive list.
The relevant biomarker panel depends on the specific cancer.
A gene name alone does not establish that a finding is actionable. The type of alteration and supporting evidence must also be considered.
Tumour mutational burden, or TMB, estimates the number of certain genetic alterations in tumour DNA, often reported per million DNA bases examined. It has been studied as an immunotherapy biomarker and has clinical uses in selected settings.
TMB should not be interpreted in isolation.
Its usefulness varies with cancer type, assay, treatment setting, and regulatory and guideline context. Thresholds and results from different assays may not be interchangeable. TMB is not a universal immunotherapy test.
Tumours may release fragments of DNA into the bloodstream. This is called circulating tumour DNA, or ctDNA. Testing ctDNA from blood is often called a liquid biopsy.
Liquid biopsy may help when:
A negative liquid biopsy does not rule out a relevant mutation.
Some tumours release little DNA into blood. Tumour tissue may still need to be tested. Blood findings also require expert interpretation because not every detected DNA change comes from the cancer.
Can provide:
Can provide:
Liquid biopsy is a powerful tool, but it does not completely replace tissue biopsy in most newly diagnosed cancers.
Read more about biopsy and cancer diagnosis.
MRD may mean Minimal Residual Disease or, in some contexts, Molecular Residual Disease. You may also see the term measurable residual disease, especially in blood cancers.
Highly sensitive ctDNA tests are being studied and used in selected clinical settings to detect tiny amounts of tumour-derived DNA after treatment. MRD methods in blood cancers may also use other tests, such as flow cytometry or PCR; they are not all the same as plasma ctDNA testing.
The role of ctDNA/MRD testing is evolving rapidly and is not the same for every cancer.
For example, a validated ctDNA/MRD approach now has an FDA-authorised role in selecting additional treatment for certain patients with muscle-invasive bladder cancer after bladder removal. This does not make MRD-guided treatment appropriate for every cancer.
A positive or negative result should not automatically lead to treatment changes outside validated clinical situations. A negative result cannot guarantee that no cancer remains. Whether testing improves care must be judged for that particular cancer and decision; consumer purchase of an unvalidated test is not a substitute for this assessment.
Examines changes inside cancer cells, including changes acquired during the patient’s lifetime. It is used primarily to understand the tumour and help guide treatment.
Looks for genetic changes present in normal cells from birth that may be inherited. It usually uses blood, saliva or another normal-cell sample. Results can affect the patient’s cancer risk, screening and biological relatives.
Tumour NGS ≠ inherited genetic testing.
A tumour result may raise suspicion of an inherited alteration, but separate germline testing may be needed. Genetic counselling can help explain the implications. Learn more about tumour genetics and inherited genetics.
Genetic testing sometimes finds a DNA change whose medical significance is not yet clear. This is called a Variant of Uncertain Significance — VUS.
A VUS is not the same as a known cancer-causing or pathogenic mutation.
A VUS generally should not guide treatment or inherited-risk decisions as though it were clearly pathogenic. Classification may change as scientific knowledge develops; your clinical team can advise whether reassessment is appropriate.
Mutation found ≠ treatment automatically available.
A molecular finding does not automatically mean there is an approved treatment, that it is appropriate for that cancer, that the patient will respond, that the medicine is available or that treatment should change.
Decisions also depend on:
Molecular information must be interpreted clinically, not simply read from a laboratory report.
An actionable biomarker is a molecular finding that may influence a clinical decision. Actionability exists at different levels. A finding may be linked to:
Not all actionable findings have the same level of evidence.
A research possibility is not equivalent to a proven treatment option for an individual patient.
Testing needs adequate tumour material. Problems may occur when a biopsy is very small, few tumour cells are present, tissue is damaged, DNA or RNA quality is poor, or the sample has already been used for several tests.
“Insufficient tissue” does not mean that the patient has no mutation. It means the laboratory could not reliably complete the test.
Another tissue sample or liquid biopsy may sometimes be considered, depending on safety and the clinical question.
Tissue is valuable. Pathology material may be needed for diagnosis, IHC, molecular testing and future testing. Modern oncology tries to use limited biopsy material carefully.
Choosing the right tests in the right order can help preserve valuable tissue.
Ask your team whether adequate material remains and how the pathology laboratory retains the sample.
Cancer biology can evolve as the disease changes or after treatment. A biomarker detected initially may remain present, become undetectable or be joined by additional resistance alterations. Different tumour sites may also have different features.
In selected situations, repeat tissue biopsy or liquid biopsy may be useful after progression.
Repeat testing is not necessary after every treatment change. It depends on the cancer and clinical situation.
No. Relevant factors may include PD-L1, MSI/MMR, TMB in selected settings, tumour type, disease stage, treatment combination and the overall clinical context.
No single biomarker perfectly predicts immunotherapy benefit across all cancers.
Read more about immunotherapy and other cancer treatments.
Targeted medicines interfere with particular cancer-driving pathways. Identifying the relevant biological target can be essential before using certain treatments.
For biomarker-selected treatments, benefit usually depends on the cancer having the feature that the medicine is designed to target. However, a matching result does not guarantee response, and not every targeted medicine requires a molecular test.
Not every detected molecular alteration is a true cancer driver.
Biomarker findings are one part of choosing an appropriate treatment.
Possible times include:
The right time depends on the specific cancer and what decision needs to be made.
CANCER AWARE · YOUR APPOINTMENT CHECKLIST
Testing should answer a clinical question.
Not necessarily. They answer different questions.
Not necessarily. Some tumours release little ctDNA.
No. The evidence and treatment options vary widely.
Not necessarily. Germline testing is a separate question; relatives need their own assessment when indicated.
No. It is an imperfect biomarker whose role differs between cancers.
Not necessarily. Testing is most useful when the result can meaningfully inform care.
Precision oncology uses information about the cancer type, stage, pathology, biomarkers, molecular alterations and patient characteristics to make treatment decisions more individualised.
Precision oncology does not mean that every patient receives a unique drug.
It means choosing treatment using the best available biological and clinical information. Testing cannot promise to identify an effective treatment.
Some biomarkers provide prognostic information, but prognosis is rarely determined by one test alone. The overall picture includes cancer type, stage, tumour biology, patient health, treatments available and response to treatment.
A molecular result is one part of the overall clinical picture.
Cancer biomarker testing can be extremely powerful when it answers the right clinical question. The goal is not to perform every possible test. The goal is to identify information that can genuinely help guide care.
Diagnosis → Stage → Relevant biomarker → Appropriate test → Clinical interpretation → Treatment decision
This educational overview draws on authoritative patient resources, companion-diagnostic information and oncology recommendations. The references explain principles; they do not establish eligibility for an individual test or medicine.
Foundational ctDNA guidance is supplemented by continuing clinical research. MRD evidence is changing; current cancer-specific guidelines and local approvals should be checked before any treatment decision. FDA authorisation describes the United States and does not establish approval or availability in every country.
Reference to these sources does not imply endorsement or affiliation.
Dr Hakeem Ansar Hussain
Medical Oncologist
Last medically reviewed:
The information on Cancer Aware is provided for general education and awareness only. It is not a substitute for consultation, diagnosis or treatment by a qualified healthcare professional. If you have persistent, worsening or concerning symptoms, please seek medical advice.
This page does not diagnose an individual or replace pathology review or consultation with an oncologist. Specific testing and treatment decisions depend on the individual case.
Biomarker results require professional interpretation. This page does not recommend a specific test or treatment for an individual. Test availability varies by location, and approved indications and guidelines change over time. Molecular testing should be ordered when clinically appropriate.
For lung-specific testing and treatment, explore the Lung Cancer guide.